

AN INTEGRATED APPROACH TO UNDERSTANDING COPD IN PRIMARY CARE

Chelsea Edwards,¹ Alvaro Aranda,² Victoria Carter,^{1,3} Ku-Lang Chang,⁴ Chester Fox,^{5,6} MeiLan K. Han,⁷ Alan Kaplan,^{3,8,9} Janwillem Kocks,^{3,10} Cathy Mahle,¹¹ Barry Make,¹² Wilson Pace,^{5,13} Asif Shaikh,¹¹ Neil Skolnik,^{14,15} Barbara Yawn,^{16,17} Gokul Gopalan,¹¹ David Price^{1,3,18}

¹Optimum Patient Care, Cambridge, UK ²Hospital Auxilio Mutuo, San Juan, Puerto Rico ³Observational Pragmatic Research Institute, Singapore; ⁴University of Florida College of Medicine, Gainesville, FL, USA ⁵DARTNet Institute, Aroua, USA; ⁶University at Buffalo, Buffalo, NY, USA ⁷Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI ⁸Family Physician Airways Group of Canada, Stouffville, Ontario ⁹University of Toronto, Toronto, Canada ¹⁰General Practitioners Research Institute, Groningen, Netherlands ¹¹Boehringer Ingelheim, Ridgefield, CT, USA ¹²Department of Medicine, National Jewish Health, Denver, CO, USA ¹³University of Colorado, Denver, USA ¹⁴Thomas Jefferson University, Jenkintown, PA, USA; ¹⁵Abington Jefferson Health, Jenkintown, PA, USA ¹⁶University of Minnesota, Minneapolis, USA; ¹⁷COPD Foundation, Washington DC, USA ¹⁸University of Aberdeen, Aberdeen, UK

Introduction

- The APEX COPD (Advancing the Patient Experience in COPD) initiative aims to:
 - capture key clinically relevant information on COPD patients (from multiple sources) with maximal efficiency,
 - present these data to clinicians and patients in a structured, clinically useful format at the point of care (PoC) during the office visit, and
 - analyse this data to answer key research questions relating to COPD in primary care.

Aim

- To create via expert consensus, a standardized list of variables for inclusion in the APEX COPD registry.

Methods

- A modified Delphi process was used to reach consensus on a minimum set of variables (core variables) to capture in the APEX COPD registry, from 3 sources:
 1. Electronic Health Records (EHRs)
 2. Patient Reported Information and Patient Reported Outcomes (PRI/PROs)
 3. During the office visit (i.e. at PoC)
- The Delphi panel comprised 14 US and international COPD experts.
- The process consisted of 3 iterative rounds (**Figure 1 on QrC**).

Results (Text)

- An initial set of 189 variables were collated from current COPD guidelines including those from GOLD, ATS and ERS.¹⁻⁶
- Of the initial 189 collated variables (plus an additional 6 variables recommended by the panel at round 1), the Delphi panel agreed to collect (**Figure 1 on QrC**):
 1. 115 from EHRs,
 2. 34 from patients themselves (i.e. PRI/PRO) and
 3. 5 during the office visit
- The agreed APEX COPD registry variables are summarized in **Figure 1**.

CONCLUSIONS

COPD experts agreed on core variables to collect in the APEX COPD registry.


These variables will be collated from existing EHRs and from patients themselves (using questionnaires and during office visits) from 3000+ COPD patients in primary care across the USA.



More information on both methodology and results may be accessed by simply scanning the QrC

Results (Figures)

Figure 1



Abbreviations: APEX: Advancing the Patient Experience; COPD: Chronic Obstructive Pulmonary Disease; Dx: diagnosis; EHR: Electronic Health Record; GOLD: Global Initiative for Chronic Obstructive Lung Disease; PoC: Point of Care at office visit; PRI/PRO: Patient Reported Information/Patient Reported Outcomes; QoL: Quality of Life; RTI: respiratory tract infection; Tx: treatment

The Future

- Data will be integrated and stored in the APEX COPD database and made available for COPD-related research.
- Data will be used to analyze COPD natural history, clinical outcomes, safety, and cost effectiveness of COPD treatments currently used in primary care across the USA.

Acknowledgments/Disclosures

APEX COPD is conducted by Optimum Patient Care (OPC) Global Limited, and co-funded by OPC Global and Boehringer Ingelheim Pharmaceuticals, Inc. The author(s) meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors received no direct compensation related to the development of the manuscript. Writing, editorial support, and/or formatting assistance was provided by Agnes Tan, Dip.ASc, and Audrey Ang, BSc (Hons), of OPRI, Singapore, which was funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.

References

1. Qaseem A, et al. *Ann Intern Med.* 2007;147(9):633-638.
2. Celli BR, et al. *Eur Respir J.* 2004;23(6):932-946.
3. Wedzicha JA, et al. *Eur Respir J.* 2017;50(3). doi:10.1183/13993003.02265-2016
4. Wedzicha JA, et al. *Eur Respir J.* 2017;49(3). doi:10.1183/13993003.00791-2016
5. Rennard S, et al. *COPD.* 2013;10(3):378-389. doi:10.3109/15412555.2013.801309
6. Singh D, et al. *Eur Respir J.* 2019;53(5). doi:10.1183/13993003.00164-2019